Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 31 Oct 2020 - 6 Nov 2020
RESEARCH TYPE:Psychology
STUDY TYPE:Human Studies, Pharmacology/Drug Development
PAIN TYPE:Migraine/Headache
DATE PUBLISHED: 2020 Oct 31
JOURNAL:Headache
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33128398?dopt=Abstract
OnabotulinumtoxinA (BTX) has become a mainstream treatment for chronic migraine (CM). Patients often have varied expectations for treatment success but little is known about how these initial impressions influence continuation of therapy.
